STOCKS TELEGRAPH

Tag: BriaCell Stock

  • BriaCell Therapeutics (BCTX) Sees Stock Boost On Promising Trial News

    BriaCell Therapeutics (BCTX) Sees Stock Boost On Promising Trial News

    As of the last check today, BriaCell Therapeutics Corp. (NASDAQ: BCTX) shares were trading 23.20% up at $4.62 on the stock charts. The surge followed the company’s positive clinical trial results.

    Excellent Results for HR+ Metastatic Breast Cancer

    Following the publication of revised results from its Phase 2 study assessing the Bria-IMT regimen in conjunction with checkpoint inhibitors (CPI), which demonstrated improved survival outcomes in patients with metastatic breast cancer (MBC), BCTX stock experienced a strong increase.

    Patients with late-stage MBC, especially those with hormone receptor-positive (HR+) illness, were the focus of the Phase 2 investigation. Twenty-five of the 37 patients who received treatment with BriaCell’s current pivotal Phase 3 formulation of Bria-IMT were found to be HR+.

    The median survival for these patients was 17.3 months, which was higher than the 14.4-month survival with TRODELVY, an antibody-drug conjugate (ADC) that is thought to be the standard of therapy for this population.

    Boosting Triple-Negative Breast Cancer Outcomes

    In the triple-negative breast cancer (TNBC) group, a particularly difficult subtype devoid of HER2, progesterone, and estrogen receptors, the Bria-IMT + CPI regimen also produced noteworthy outcomes. While survival in this group was comparable to that achieved with TRODELVY, it exceeded traditional chemotherapy outcomes by 70%, underscoring the regimen’s therapeutic potential.

    Well-Tolerated Therapy Shows Broad Potential

    There have been no documented treatment-related discontinuations as of yet, indicating that the Bria-IMT regimen has shown excellent tolerability. These results support BriaCell’s theory that Bria-IMT and CPI together might provide HR+ and TNBC patients—groups who presently have few therapy options and dismal prognoses—with a useful treatment option.

    Of the 54 patients with MBC who were significantly pre-treated in BriaCell’s Phase 2 study, 37 were given the formulation that is currently being employed in its key Phase 3 trial. BCTX will continue evaluating overall survival as the primary endpoint in this ongoing study, aiming to confirm the promising Phase 2 results and address the unmet medical needs in this difficult-to-treat population.

  • BriaCell Therapeutics Corp. (BCTX) stock increased over 10% in Pre-Market: Let’s find out why

    BriaCell Therapeutics Corp. (BCTX) stock increased over 10% in Pre-Market: Let’s find out why

    Share of BriaCell Therapeutics Corp. (BCTX) surpassed 10% in the pre-market trading session today. BCTX stock saw a push of 13.82% to reach $5.93 a share at the time of this writing. It seems that BCTX stock continued the rising momentum as it went up by 18.95% at the previous closing. But what made the stock high in the stock market? Let’s try to find it.

    What’s happening?

    There is no particular news by the  BriaCell stock today to justify the bull. No signs of analyst upgrades or upswing BCTX per share targeted price to explain the rally. However, BrialCell announced on March 30 about its selection to present the analysis result of its research related to breast cancer at the American Association for Cancer Research (AACR) Annual Meeting 2021. The dates announced for the meeting were April 10 to 15 and May 17 – 21.

    The first week of the meeting is ongoing and there is a strong possibility that investors are responding to the results announced by the company in the meeting. The analysis result to be announced in the meeting would be related to the clinical analysis and pathological data of BriaCell’s lead product, Bria-IMT for treatment of advanced breast cancer as well as Phase I/IIa clinical study of Bria-IMTin combination with immune checkpoint inhibitors which include pembrolizumab, a Merck’s product, and INCMGA00012, a product of Incyte Corporation.

    BCTX stock previous news:

    On February 26, 2021, BCTX stock closed the underwritten public offering of its common units. 4,852,353 common units were offered in that offering with US$4.25 per unit purchase price. Each unit consisted of one share of common stock of BCTX along with one warrant to the purchase of one share of BCTX’s common stock. 1,030,000 pre-funded units were offered at the public price of  US$4.24 each and consisted of a pre-funded purchase warrant of common stock and one Warrant. The US$25 million gross proceeds resulted from this offering without deducting the underwriting discounts and other related expenses.

    Conclusion:

    BCTX stock price is continuously rising despite no recent news by BriaCell Therapeutics. It would be interesting to see how long this trend would continue in the future. The final results of research related to breast cancer would greatly influence the future of the BriaCell stock.